Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 7/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.35 |
| ▸ | ADCY10 | Q96PN6 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6179337 | 0.91 | GAA (0.43) | GAAHTR3AHTR4KDM4EALDH1A1 | |
| SCHEMBL5777321 | 0.86 | HTR3A (0.43) | HTR3AHTR4KDM4EALDH1A1MAPT | |
| SCHEMBL5889428 | 0.83 | HTR3A (0.55) | GAAHTR3AHTR4KDM4EALDH1A1 | |
| SCHEMBL6177033 | 0.80 | GAA (0.44) | GAAHTR3AHTR4KDM4EALDH1A1 | |
| SCHEMBL6178418 | 0.77 | ALDH1A1 (0.45) | GAAKDM4EALDH1A1MAPTADCY10 | |
| SCHEMBL6178115 | 0.77 | HTR3A (0.42) | HTR3AHTR4KDM4EKCNH2 | |
| SCHEMBL6762031 | 0.76 | BAZ2B (0.45) | GAAHTR3AHTR4KDM4EALDH1A1 | |
| SCHEMBL6765012 | 0.75 | HTR4 (0.57) | HTR3AHTR4KCNH2 | |
| SCHEMBL5779209 | 0.74 | HTR4 (0.79) | HTR3AHTR4KCNH2 | |
| SCHEMBL6179085 | 0.74 | GAA (0.48) | GAAKDM4EALDH1A1MAPTNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7012080-B2 | Imidazopyridine compounds as 5-HT4 receptor agonists | PFIZER INC. (US) | 2006-03-14 | — | — | US | disclosed |
| EP-1440071-B1 | IMIDAZOPYRIDINE COMPOUNDS AS 5-HT 4? RECEPTOR MODULATORS | PFIZER (US) | 2005-10-26 | — | — | EP | disclosed |
| US-6951867-B2 | N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators | PFIZER INC. (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1543004-A1 | N-SUBSTITUTED PIPERIDINYL-IMIDAZOPYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS | PFIZER INC. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040266814-A1 | Imidazopyridine compounds having 5-HT4 receptor agonistic activity and 5-HT3 receptor antagonistic activity | PFIZER INC | 2004-12-30 | — | — | US | disclosed |
| US-20040127514-A1 | N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators | PFIZER INC | 2004-07-01 | — | — | US | disclosed |
| US-20040122043-A1 | Imidazopyridine compounds as 5-HT4 receptor agonists | PFIZER INC | 2004-06-24 | — | — | US | disclosed |
| WO-2004026868-A1 | N-SUBSTITUTED PIPERIDINYL-IMIDAZOPYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS | PFIZER JAPAN INC. (JP) | 2004-04-01 | — | — | WO | disclosed |
| US-20040034226-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | UCHIDA CHIKARA (JP) | 2004-02-19 | — | — | US | disclosed |
| US-6624162-B2 | 5-HT4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, Functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. | PFIZER INC. | 2003-09-23 | — | — | US | disclosed |
| US-20030092699-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | PFIZER INC. | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092699-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | HTR4, HRH4, HRH2 | GAA 3781/4885HTR3A 28/4885HTR4 1/4885 |
| US-20040127514-A1 | N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators | HTR4, HRH4, HRH2 | GAA 3732/4885HTR3A 35/4885HTR4 1/4885 |
| US-20040266814-A1 | Imidazopyridine compounds having 5-HT4 receptor agonistic activity and 5-HT3 receptor antagonistic activity | HTR4, HRH4, GIPR | GAA 3755/4885HTR3A 11/4885HTR4 1/4885 |
| US-20040122043-A1 | Imidazopyridine compounds as 5-HT4 receptor agonists | HTR4, GPR4, HRH4 | GAA 3990/4885HTR3A 35/4885HTR4 1/4885 |
| US-20040034226-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | HRH4, HTR4, HRH2 | GAA 3701/4885HTR3A 27/4885HTR4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.